AAIC 2025 Abstract
Proteomic subtyping of Alzheimer's disease CSF links blood‐brain barrier dysfunction to reduced levels of tau and synaptic biomarkers
By Madison C. Bangs, Joshna Dharmendrabhai Gadhavi, Emma Kathleen Carter, Show 9 more authorsNicholas T. Seyfried
Study in peopleMechanisms
Abstract
Background: Neuropathological changes in Alzheimer's disease (AD) begin decades before cognitive symptoms appear, highlighting the need for early detection to enable prevention and treatment.
